Literature DB >> 15465830

Involvement of domain II in toxicity of anthrax lethal factor.

Xudong Liang1, John J Young, Sherrie A Boone, David S Waugh, Nicholas S Duesbery.   

Abstract

Anthrax lethal factor (LF) is a Zn2+ -metalloprotease that cleaves and inactivates mitogen-activated protein kinase kinases (MEKs). We have used site-directed mutagenesis to identify a cluster of residues in domain II of LF that lie outside the active site and are required for cellular proteolytic activity toward MEKs. Alanine substituted for Leu293, Lys294, Leu514, Asn516, or Arg491 caused a 10-50-fold reduction in LF toxicity. Further, whereas pairwise substitution of alanine for Leu514 and either Leu293, Lys294, or Arg491 completely abrogated LF toxicity, pairwise mutation of Leu514 and Asn516 resulted in toxicity comparable with N516A alone. The introduction of these mutations reduced LF-mediated cleavage of MEK2 in cell-based assays but altered neither the ability of LF to bind protective antigen nor its ability to translocate across a membrane. Interestingly, direct in vitro measurement of LF activity indicated that decreased toxicity was not always accompanied by reduced proteolytic activity. However, mutations in this region significantly reduced the ability of LF to competitively inhibit B-Raf phosphorylation of MEK. These results provide evidence that elements of domain II are involved in the association of LF into productive complex with MEKs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465830     DOI: 10.1074/jbc.M409105200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

2.  An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.

Authors:  Nam-Kyu Lim; Jung-Hwan Kim; Mee Sook Oh; Sangyoon Lee; Se-Yeon Kim; Keun-Soo Kim; Hyun-Jung Kang; Hyo Jeong Hong; Kyung-Soo Inn
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Anthrax lethal toxin disrupts the endothelial permeability barrier through blocking p38 signaling.

Authors:  Tiegang Liu; Erica Milia; Rod R Warburton; Nicholas S Hill; Matthias Gaestel; Usamah S Kayyali
Journal:  J Cell Physiol       Date:  2012-04       Impact factor: 6.384

4.  Identification of a Substrate-selective Exosite within the Metalloproteinase Anthrax Lethal Factor.

Authors:  Allison B Goldberg; Eunice Cho; Chad J Miller; Hua Jane Lou; Benjamin E Turk
Journal:  J Biol Chem       Date:  2016-12-01       Impact factor: 5.157

5.  Substrate recognition of anthrax lethal factor examined by combinatorial and pre-steady-state kinetic approaches.

Authors:  Maria Yu Zakharova; Nikita A Kuznetsov; Svetlana A Dubiley; Arina V Kozyr; Olga S Fedorova; Dmitry M Chudakov; Dmitry G Knorre; Igor G Shemyakin; Alexander G Gabibov; Alexander V Kolesnikov
Journal:  J Biol Chem       Date:  2009-04-09       Impact factor: 5.157

6.  An anthrax lethal factor mutant that is defective at causing pyroptosis retains proapoptotic activity.

Authors:  Stephanie Ngai; Sarah Batty; Kuo-Chieh Liao; Jeremy Mogridge
Journal:  FEBS J       Date:  2009-11-18       Impact factor: 5.542

7.  Insights into the anthrax lethal factor-substrate interaction and selectivity using docking and molecular dynamics simulations.

Authors:  Georgios A Dalkas; Athanasios Papakyriakou; Alexios Vlamis-Gardikas; Georgios A Spyroulias
Journal:  Protein Sci       Date:  2009-08       Impact factor: 6.725

Review 8.  Anthrax lethal toxin and the induction of CD4 T cell immunity.

Authors:  Stephanie Ascough; Rebecca J Ingram; Daniel M Altmann
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

9.  Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.

Authors:  Stephanie Ascough; Rebecca J Ingram; Karen K Chu; Catherine J Reynolds; Julie A Musson; Mehmet Doganay; Gökhan Metan; Yusuf Ozkul; Les Baillie; Shiranee Sriskandan; Stephen J Moore; Theresa B Gallagher; Hugh Dyson; E Diane Williamson; John H Robinson; Bernard Maillere; Rosemary J Boyton; Daniel M Altmann
Journal:  PLoS Pathog       Date:  2014-05-01       Impact factor: 6.823

10.  A potent tumor-selective ERK pathway inactivator with high therapeutic index.

Authors:  Zehua Zuo; Jie Liu; Zhihao Sun; Rachel Silverstein; Meijuan Zou; Toren Finkel; Thomas H Bugge; Stephen H Leppla; Shihui Liu
Journal:  PNAS Nexus       Date:  2022-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.